<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9825618</article-id>
    <article-id pub-id-type="pmid">36243960</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkac812</article-id>
    <article-id pub-id-type="publisher-id">gkac812</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>DRESIS: the first comprehensive landscape of drug resistance information</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Sun</surname>
          <given-names>Xiuna</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <aff><institution>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba–Zhejiang University Joint Research Center of Future Digital Healthcare</institution>, Hangzhou 330110, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Yintao</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Hanyang</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhou</surname>
          <given-names>Ying</given-names>
        </name>
        <aff><institution>The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shi</surname>
          <given-names>Shuiyang</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Zhen</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>He</surname>
          <given-names>Xin</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <aff><institution>Zhejiang University–University of Edinburgh Institute, Zhejiang University</institution>, Haining 314499, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4728-7702</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Hanyu</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Fengcheng</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yin</surname>
          <given-names>Jiayi</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7619-2975</contrib-id>
        <name>
          <surname>Mou</surname>
          <given-names>Minjie</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yunzhu</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Qiu</surname>
          <given-names>Yunqing</given-names>
        </name>
        <aff><institution>The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8069-0053</contrib-id>
        <name>
          <surname>Zhu</surname>
          <given-names>Feng</given-names>
        </name>
        <!--zhufeng@zju.edu.cn-->
        <aff><institution>College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <aff><institution>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba–Zhejiang University Joint Research Center of Future Digital Healthcare</institution>, Hangzhou 330110, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Email: <email>zhufeng@zju.edu.cn</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first 4 authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>06</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-10-16">
      <day>16</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>16</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <volume>51</volume>
    <issue>D1</issue>
    <fpage>D1263</fpage>
    <lpage>D1275</lpage>
    <history>
      <date date-type="accepted">
        <day>11</day>
        <month>10</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>22</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="received">
        <day>09</day>
        <month>8</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkac812.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Widespread drug resistance has become the key issue in global healthcare. Extensive efforts have been made to reveal not only diverse diseases experiencing drug resistance, but also the six distinct types of molecular mechanisms underlying this resistance. A database that describes a comprehensive list of diseases with drug resistance (not just cancers/infections) and all types of resistance mechanisms is now urgently needed. However, no such database has been available to date. In this study, a comprehensive database describing drug resistance information named ‘DRESIS’ was therefore developed. It was introduced to (<bold>i</bold>) systematically provide, for the first time, all existing types of molecular mechanisms underlying drug resistance, (ii) extensively cover the widest range of diseases among all existing databases and (<bold>iii</bold>) explicitly describe the clinically/experimentally verified resistance data for the largest number of drugs. Since drug resistance has become an ever-increasing clinical issue, DRESIS is expected to have great implications for future new drug discovery and clinical treatment optimization. It is now publicly accessible without any login requirement at: <ext-link xlink:href="https://idrblab.org/dresis/" ext-link-type="uri">https://idrblab.org/dresis/</ext-link></p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <caption>
            <p>DRESIS constructed in this work systematically provides, for the first time, all six types of molecular mechanisms underlying drug resistance, covers the widest range of diseases among existing databases and describes the clinically/experimentally verified resistance data for &gt;20 000 drugs.</p>
          </caption>
          <graphic xlink:href="gkac812figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Zhejiang Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100004731</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>LR21H300001</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>U1909208</award-id>
        <award-id>81872798</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National High-Level Talents Special Support Plan of China</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Fundamental Research Fund of Central University</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2018QNA7023</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Key R&amp;D Program of Zhejiang Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2020C03010</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Chinese ‘Double Top-Class’ Universities</institution>
          </institution-wrap>
        </funding-source>
        <award-id>181201*194232101</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Westlake Laboratory (Westlake Laboratory of Life Science &amp; Biomedicine)</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Alibaba-Zhejiang University</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Alibaba Cloud</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Information Tech Center of Zhejiang University</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="13"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Widespread drug resistance has emerged as a key issue in local/global healthcare, and many regional/worldwide action plans have therefore been set up by both local governments and the World Health Organization (WHO; <xref rid="B1" ref-type="bibr">1–3</xref>). To address such a critical issue, extensive efforts have been devoted to discovering new compounds (e.g. allosteric modulators) (<xref rid="B4" ref-type="bibr">4–7</xref>), proposing efficacious drug combinations (<xref rid="B8" ref-type="bibr">8–10</xref>) and developing new biotechnology (e.g. PROTAC) (<xref rid="B11" ref-type="bibr">11–13</xref>) which effectively overcome the corresponding resistance (<xref rid="B14" ref-type="bibr">14–16</xref>). As is known, the success of these efforts is extensively dependent on the thorough understanding of the molecular mechanisms underlying each type of resistance (<xref rid="B17" ref-type="bibr">17–22</xref>). Therefore, a large number of studies (&gt;1000 papers per year recorded by PubMed) have been conducted and published in recent years to reveal those important mechanisms (<xref rid="B23" ref-type="bibr">23–28</xref>)</p>
    <p>Among these studies, the aberration in a drug’s therapeutic target (e.g. mutation) has been reported as one of the most important mechanisms underlying existing types of resistance (<xref rid="B29" ref-type="bibr">29–32</xref>), which inspires researchers to discover alternative therapies that can circumvent this type of mechanism (<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>). However, besides target aberration, additional types of mechanisms have been reported to play key roles (<xref rid="B35" ref-type="bibr">35–38</xref>), which, as shown in Figure <xref rid="F1" ref-type="fig">1</xref>, comprise (i) irregularity in drug uptake and efflux (<xref rid="B39" ref-type="bibr">39</xref>), (ii) drug inactivation due to enzymatic modifications (<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>), (iii) epigenetic alteration of DNA, RNA or protein (<xref rid="B42" ref-type="bibr">42–44</xref>), (iv) unusual activation of pro-survival pathways (<xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B46" ref-type="bibr">46</xref>) and (v) regulation by the disease microenvironment (<xref rid="B47" ref-type="bibr">47</xref>,<xref rid="B48" ref-type="bibr">48</xref>). These five mechanisms are distinct from target aberration, and have thus attracted extensive interest from related research communities (<xref rid="B44" ref-type="bibr">44–50</xref>).</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Schematic illustration of the six types of mechanism that are reported to play an essential role in the determination of a drug's resistance. These six mechanism types are: aberration of the drug's therapeutic target (ADTT), irregularity in drug uptake and drug efflux (IDUE), drug inactivation by structure modification (DISM), epigenetic alteration of DNA, RNA and protein (EADR), unusual activation of the pro-survival pathway (UAPP) and regulation by the disease microenvironment (RTDM). The six types of key resistance molecule (indicated using black italic font, i.e. therapeutic target, drug transporter, drug-metabolizing enzyme, epigenetics-related molecule, pathway activator/suppressor and microenvironment regulator) were considered as essential for the mechanisms of ADTT, IDUE, DISM, EADR, UAPP and RTDM, respectively. (The figure was created with Biorender.com.)</p>
      </caption>
      <graphic xlink:href="gkac812fig1" position="float"/>
    </fig>
    <p>Moreover, a particular resistance has also been reported to be made up of multiple mechanism types, which further reminds us about the great complexity of the studied types of resistance (<xref rid="B51" ref-type="bibr">51–54</xref>). In other words, before responding to a drug’s resistance, it is critical to acquire explicit knowledge of its mechanism(s), and a knowledge base providing all existing types (a total of six types) of mechanism underlying each drug’s resistance is therefore greatly required (<xref rid="B55" ref-type="bibr">55–57</xref>).</p>
    <p>So far, a variety of valuable knowledge bases have been developed to provide drug resistance-related information. These databases describe drug resistance information for certain disease classes, such as cancer [e.g. CancerDR (<xref rid="B58" ref-type="bibr">58</xref>), KinaseMD (<xref rid="B59" ref-type="bibr">59</xref>)], virus infection [e.g. Stanford HIV Database (<xref rid="B60" ref-type="bibr">60</xref>), HBVdb (<xref rid="B61" ref-type="bibr">61</xref>)], bacterial infection [e.g. CARD (<xref rid="B62" ref-type="bibr">62</xref>), MEGARes (<xref rid="B63" ref-type="bibr">63</xref>)] and fungal infection [MARDy (<xref rid="B64" ref-type="bibr">64</xref>)]. These databases have attracted widespread interest from research communities (<xref rid="B58" ref-type="bibr">58–71</xref>). However, as reported, there are far more diseases suffering from resistance than just cancer/infection (<xref rid="B72" ref-type="bibr">72–76</xref>). Moreover, existing databases mainly focus on the mechanisms of target aberration, and none of them describes the five additional types. Thus, a resistance-based database covering various disease classes and diverse types of mechanism is still urgently needed.</p>
    <p>Herein, a comprehensive database for <underline>d</underline>rug <underline>resis</underline>tance information named ‘DRESIS’ was therefore developed. First, a comprehensive literature review was conducted by searching PubMed, which led to &gt;20 000 drugs with clinically/experimentally validated resistance information. Second, the diseases corresponding to resistance to these drugs were manually retrieved from the literature, which, to the best of our knowledge, covered a much wider range of disease classes compared with other available databases. Finally, for all collected drugs, the molecular mechanisms underlying each type of resistance were systematically collected, and the disease- and tissue-specific abundance of the resistance-relevant molecules were analyzed and provided in the DRESIS database.</p>
    <p>All in all, the DRESIS database was introduced to (i) systematically provide, for the first time, all existing types of molecular mechanisms underlying drug resistance, (ii) extensively cover the widest range of diseases among all available databases and (iii) explicitly describe the clinically/experimentally verified resistance data for the largest number of drugs among existing databases. Since drug resistance has become an ever-increasing clinical issue, our DRESIS database (<ext-link xlink:href="https://idrblab.org/dresis/" ext-link-type="uri">https://idrblab.org/dresis/</ext-link>) is expected to have great implications for the future of new drug discovery.</p>
  </sec>
  <sec id="SEC2">
    <title>FACTUAL CONTENT AND DATA RETRIEVAL</title>
    <sec id="SEC2-1">
      <title>Systematic collection of the drug resistance information</title>
      <p>The drug resistance data provided in DRESIS were collected using the following procedure. First, a large number of drugs were collected from different well-established pharmaceutical databases, which resulted in &gt;2000 approved drugs [collected from the website of the US Food and Drug Administration (FDA)], &gt;9000 drugs in clinical trials [from ClinicalTrial.gov (<xref rid="B77" ref-type="bibr">77</xref>) and TTD (<xref rid="B78" ref-type="bibr">78</xref>)] and &gt;32 000 pre-clinical/investigative agents [from DrugBank (<xref rid="B79" ref-type="bibr">79</xref>), CCNSC (<xref rid="B80" ref-type="bibr">80</xref>) and TTD (<xref rid="B78" ref-type="bibr">78</xref>)]. Second, the resistance information of these drugs was systematically identified based on a comprehensive literature review in PubMed using the keyword combinations of ‘Drug Name + drug resistance’, ‘Drug Name + susceptibility’, ‘Drug Name + drug sensitivity’, ‘Drug Name + drug response’, and so on. As a result, a total of 816 FDA-approved, 336 pre-clinical/clinical trials and 19 675 investigative drugs were identified with either clinically reported or <italic toggle="yes">in vivo</italic>/cell line-validated resistance data. Third, the additional information on the corresponding disease for each type of resistance was systematically retrieved from the original publications. All diseases were standardized using the latest WHO International Classification of Diseases [ICD-11 (<xref rid="B81" ref-type="bibr">81</xref>)], which resulted in a total of 395 disease classes defined by ICD-11. Moreover, 232 (58.7%) out of the 395 disease classes covered by DRESIS belonged to either cancer or infection, and this result was consistent with our previous understanding that the disease indications suffering from resistance were more extensive than just cancer/infection (<xref rid="B72" ref-type="bibr">72–76</xref>). Some of the typical DRESIS diseases (other than cancers and infections) included: Alzheimer's disease, diabetes mellitus, hypertension and Parkinson disease. To the best of our knowledge, the systematic resistance data of these diseases (beyond both cancers and infections) were provided, for the first time, among all existing pharmaceutical knowledge bases.</p>
      <p>In the online database, detailed descriptions of the resistance information for each drug were systematically provided. In the webpage of a typical drug ‘doxorubicin’ (as illustrated in Figure <xref rid="F2" ref-type="fig">2</xref>), its general pharmaceutical information is described in the upper section, which included: Drug Name, Drug Synonyms, Disease Indications (together with the corresponding Clinical Status of the drug), Drug Structures (downloadable in both 2D and 3D formats), Drug Target and External Linkage to other well-established molecular biological databases such as PubChem (<xref rid="B82" ref-type="bibr">82</xref>), DrugBank (<xref rid="B79" ref-type="bibr">79</xref>), TTD (<xref rid="B83" ref-type="bibr">83</xref>), VARIDT (<xref rid="B84" ref-type="bibr">84</xref>) and INTEDE (<xref rid="B85" ref-type="bibr">85</xref>). Moreover, the resistance information of the studied drug is explicitly illustrated in the lower section of Figure <xref rid="F2" ref-type="fig">2</xref>, which describes a list of diseases with reported resistance for the studied drug. For each drug, multiple diseases were usually found with reported resistance, and these diseases were classified according to their types of resistance evidence (clinically reported, validated by an <italic toggle="yes">in vivo</italic> model or identified using a cell line experiment). All in all, the resistance-based relationships between drugs and diseases were established in DRESIS, and the resulting data were well organized for access and downloading by users.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Detailed descriptions on the resistance information of each drug (using doxorubicin as an example). General pharmaceutical data are provided in the upper section, which includes Drug Name, Drug Synonyms, Disease Indications (together with the corresponding Clinical Status of the drug), Drug Structures (downloadable in both 2D and 3D formats), Drug Target and External Linkage to other molecular biological databases. The resistance information of the studied drug is illustrated in the lower section, which describes a list of diseases with reported resistance for the drug. For a drug, multiple diseases were usually found with reported resistances, and the diseases were classified here according to their types of resistance evidence (clinically reported, validated by an <italic toggle="yes">in vivo</italic> model or identified using a cell line experiment).</p>
        </caption>
        <graphic xlink:href="gkac812fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC2-2">
      <title>Diverse types of mechanism underlying drug resistance</title>
      <p>Six types of mechanism have been reported to play crucial roles in determining the resistance of drugs (<xref rid="B33" ref-type="bibr">33–36</xref>,<xref rid="B49" ref-type="bibr">49</xref>). As shown in Figure <xref rid="F1" ref-type="fig">1</xref>, these six mechanism types are aberration of the drug's therapeutic target (ADTT), irregularity in drug uptake and drug efflux (IDUE), drug inactivation by structure modification (DISM), epigenetic alteration of DNA, RNA and protein (EADR), unusual activation of the pro-survival pathway (UAPP) and regulation by the disease microenvironment (RTDM). Moreover, the resistance factors key in the six mechanisms were also highlighted in Figure <xref rid="F1" ref-type="fig">1</xref> (in black italic font). In particular, six types of key resistance molecules (therapeutic target, drug transporter, drug-metabolizing enzyme, epigenetics-relevant molecule, pathway activator/suppressor and microenvironment regulator) were shown in DRESIS as essential for the mechanisms of ADTT, IDUE, DISM, EADR, UAPP and RTDM, respectively. Based on these mechanisms, new therapeutic strategies were proposed to counteract the existing types of resistance or to optimize the available regimens for disease treatment (<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B86" ref-type="bibr">86</xref>).</p>
      <p>It is known that the resistance of a drug may be extremely complicated, involving multiple mechanism types (<xref rid="B87" ref-type="bibr">87–89</xref>). Taking the anticancer drug ‘doxorubicin’ as an example, its resistance in breast cancer was reported to not only originate from the irregularity of its transporter <italic toggle="yes">ABCB1</italic>, but to also stem from the unusual activation of the pro-survival pathway <italic toggle="yes">PI3K/AKT</italic> (<xref rid="B90" ref-type="bibr">90</xref>). In other words, the resistance of a drug may be collectively generated by multiple types of mechanisms. Therefore, DRESIS was constructed to provide a unique function of describing multiple types of resistance mechanism for each of the approved/clinical trial/pre-clinical/investigative drugs.</p>
      <sec id="SEC2-2-1">
        <title>Describing multiple types of resistance mechanisms for each drug</title>
        <p>As shown in Figure <xref rid="F3" ref-type="fig">3</xref>, an interactive graph was plotted in DRESIS to describe multiple types of resistance mechanisms for each drug, and such data were organized by both mechanism types and disease classes. Taking ‘doxorubicin’ as an example, it has six resistance mechanisms indicated by different colors in the interactive graph. The corresponding resistance diseases are shown under each mechanism, and key resistance molecules are provided for the corresponding disease. In other words, a comprehensive illustration of both resistance mechanisms and resistance diseases are provided for each drug, which can be interactively accessed online.</p>
        <fig position="float" id="F3">
          <label>Figure 3.</label>
          <caption>
            <p>Illustrating the multiple types of resistance mechanisms for the drug doxorubicin using an interactive diagram. The drug is placed in the middle and surrounded by various types of mechanisms (as illustrated on the top of this diagram). Various disease classes were linked to each mechanism type, which were further connected to key resistance molecules (illustrated in outermost leaves). Doxorubicin has six types of resistance mechanisms shown by various colors in the interactive diagram. Resistance diseases are shown under each mechanism, and key resistance molecules are given for the corresponding disease. A comprehensive illustration of resistance mechanisms and resistance diseases is provided for each drug, which can be interactively accessed online.</p>
          </caption>
          <graphic xlink:href="gkac812fig3" position="float"/>
        </fig>
        <p>Moreover, the detailed resistance mechanisms were also explicitly described in DRESIS (shown in Figure <xref rid="F4" ref-type="fig">4</xref>). Under a particular mechanism type for a specific disease, the data of key resistance molecules, type of resistance evidence and experimental details were systematically provided and organized in the drug page. A total of 2197 key resistance molecules were identified, and their specific alterations in drug resistance disease were described. Moreover, different types of resistance evidence (such as clinically reported, validated by an <italic toggle="yes">in vivo</italic> model and identified by a cell line experiment) were identified from the literature. A variety of experimental details were also provided, which included diverse experimental techniques [such as MTT assays, flow cytometry assays, disk diffusion methods, quantitative polymerase chain reaction (qPCR), western blotting and luciferase activity assays], hundreds of disease cell lines (such as A459, CaOV3, K562, MCF7 and SNU1) and infectious strains (such as <italic toggle="yes">Klebsiella pneumoniae</italic> KPLA-9, hepatitis C virus H77, <italic toggle="yes">Staphylococcus aureus</italic> RN4565 and <italic toggle="yes">Vibrio cholerae</italic> PG149a), and hundreds of <italic toggle="yes">in vivo</italic> models (such as Sur1 knockout rats, C57/BL6 mice, tumor xenograft mouse and CB17 SCID–/– mouse xenografts). Moreover, the signaling pathways (such as MAPK signaling, PI3K/AKT/mTOR, PTEN signaling and cell apoptosis) that were regulated in the resistance diseases were also identified and provided online.</p>
        <fig position="float" id="F4">
          <label>Figure 4.</label>
          <caption>
            <p>Detailed resistance mechanisms of drug that were categorized according to the disease classes. Under a mechanism type for a specific disease, the data of key resistance molecules, type of resistance evidence and experimental details are systematically shown in a typical drug page. For key resistance molecules, their alterations in resistance disease are described, and different types of resistance evidence (clinically reported, validated by <italic toggle="yes">an in vivo</italic> model or identified by a cell line experiment) were discovered. Various experimental details were described, which included: diverse experimental techniques, hundreds of disease cell lines and infectious strains, hundreds of <italic toggle="yes">in vivo</italic> models and a variety of signaling pathways regulated in the resistance diseases.</p>
          </caption>
          <graphic xlink:href="gkac812fig4" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec id="SEC2-3">
      <title>The panorama of resistant drugs for a particular disease</title>
      <p>For a specific disease, the resistance of some drugs is, on the one hand, collectively determined by multiple types of mechanisms (<xref rid="B87" ref-type="bibr">87–90</xref>). On the other hand, some molecules can also be key for the resistance of multiple drugs (<xref rid="B83" ref-type="bibr">83</xref>,<xref rid="B91" ref-type="bibr">91</xref>). Therefore, it is of extensive interest to have an overview of the comprehensive lists of both drugs and key resistance molecules for a specific disease. In this study, a panorama of resistant drugs for each disease was collected and systematically described in DRESIS. As illustrated in Figure <xref rid="F5" ref-type="fig">5</xref>, for the disease ‘breast cancer’, a full list of resistant drugs was provided using their drug IDs on the vertical axis, and another list of key resistance molecules was shown using the corresponding molecule IDs on the horizontal axis. Due to the huge amount of both drugs and key molecules involved in breast cancer (and also in many other diseases), DRESIS enabled the visualization of the entire panorama through dragging the sliders on both bottom and right sides of the interactive diagram shown in Figure <xref rid="F5" ref-type="fig">5</xref>. Different types of resistance mechanisms were indicated in the diagram using circles (with the letter ‘R’ in the middle) of different colors. By placing the mouse on any of the circles, the detailed information on mechanism type, resistant drug and key molecule could be interactively viewed. All in all, DRESIS is unique in providing a panorama that enables a full visualization of all drugs and all key molecules in the development of resistance in a disease. Such panorama diagrams are valuable for the audience to have a quick and global understanding on the resistance profile for any disease of research interest.</p>
      <fig position="float" id="F5">
        <label>Figure 5.</label>
        <caption>
          <p>A panorama diagram of resistant drugs for the disease breast cancer in DRESIS. A full list of resistant drugs is provided using the drug IDs on the vertical axis, and another list of key resistance molecules is shown by the molecule IDs on the horizontal axis. Due to the huge amount of both drugs and key molecules involved in breast cancer (also in many other diseases), DRESIS enabled the visualization of the entire panorama through dragging the sliders on both the bottom and right sides of the interactive diagram. Different types of resistance mechanisms are indicated in this diagram using circles (with the letter ‘R’ in the middle) of different colors. By placing the mouse on any of the circles, the detailed information on mechanism type, resistant drug and key molecule can be interactively viewed. This panorama diagram is valuable for the audience to have a quick and global understanding of the resistance profile for any disease of research interest.</p>
        </caption>
        <graphic xlink:href="gkac812fig5" position="float"/>
      </fig>
      <p>Besides the panorama diagram, detailed resistance mechanisms were also explicitly described in the disease webpage of DRESIS (illustrated in Figure <xref rid="F6" ref-type="fig">6</xref>). For any mechanism type of a drug, the data of the key molecule, type of resistance evidence and experimental details were also provided and organized in disease pages. The alterations of key resistance molecules in drug resistance disease and different types of resistance evidence were also provided. Moreover, the experimental details of the applied experimental techniques, disease cell lines, infectious strains, <italic toggle="yes">in vivo</italic> models and the pathways regulating the resistance disease were also collected and provided.</p>
      <fig position="float" id="F6">
        <label>Figure 6.</label>
        <caption>
          <p>Detailed resistance mechanisms of disease that were categorized according to the drug names. Under each mechanism type for specific drugs, the data of key resistance molecules, type of resistance evidence and experimental details are systematically shown in a typical disease page. For key resistance molecules, their alterations in resistance disease were described, and different types of resistance evidence (clinically reported, validated by an <italic toggle="yes">in vivo</italic> model or identified by a cell line experiment) were discovered. Various experimental details are described, which included: diverse experimental techniques, hundreds of disease cell lines and infectious strains, hundreds of <italic toggle="yes">in vivo</italic> models and a variety of signaling pathways regulated in the resistance diseases.</p>
        </caption>
        <graphic xlink:href="gkac812fig6" position="float"/>
      </fig>
    </sec>
    <sec id="SEC2-4">
      <title>Disease/tissue-specific abundances of resistant molecules</title>
      <p>Disease/tissue-specific abundances of different molecules have frequently been reported to determine drug pharmacokinetics (<xref rid="B92" ref-type="bibr">92</xref>,<xref rid="B93" ref-type="bibr">93</xref>), mitigate adverse drug reactions (<xref rid="B94" ref-type="bibr">94</xref>) and greatly affect drug efficacy (<xref rid="B95" ref-type="bibr">95</xref>). Since such disease/tissue-specific variations in the newly identified key resistant molecules were expected to inspire new therapeutic strategies (<xref rid="B96" ref-type="bibr">96–100</xref>), these data needed to be collected for future analysis. In the latest version of DRESIS, the disease/tissue-dependent abundance data of these key resistance molecules were therefore systematically collected and illustrated online.</p>
      <sec id="SEC2-4-1">
        <title>Disease-specific differential expression of the key resistance molecules</title>
        <p>For those key resistance proteins, a total of 5535 series records of the raw expression data based on the Affymetrix Human Genome U133 Plus 2.0 Array from the GEO (<xref rid="B101" ref-type="bibr">101</xref>) were first collected, and the corresponding tissue and disease information for each series were also identified. Second, by matching with the disease classes provided in DRESIS, a total of 516 series records (covering 63 DRESIS disease classes) were identified for retrieving disease-specific differential expression. Third, all series record data were processed using the well-established R package affy (<xref rid="B102" ref-type="bibr">102</xref>), and a baseline of the median intensities of protein expression were chosen for conduct normalization. Fourth, Student's <italic toggle="yes">t</italic>-test, fold change and <italic toggle="yes">Z</italic>-score were adopted to quantify the level of differential expression among sample groups, which included: the samples from the patients’ diseased tissue, samples from the normal tissue of healthy people, samples from normal tissue adjacent to disease tissue and samples from tissue other than diseased tissue of patients.</p>
        <p>For the key resistance non-coding RNAs (ncRNAs), RNA sequencing data of 9421 tumor and 8589 normal samples were <bold>first</bold> collected from two existing databases, i.e. TCGA (<xref rid="B103" ref-type="bibr">103</xref>) and Genotype-Tissue Expression (<xref rid="B104" ref-type="bibr">104</xref>). Second, these RNA sequencing data were analyzed using the uniform pipeline from the UCSC Xena project to minimize the variations induced by different sources (<xref rid="B105" ref-type="bibr">105</xref>). Third, the abundance variations of those key resistance ncRNAs between patients with the disease and healthy individuals were analyzed using Student's <italic toggle="yes">t</italic>-test, fold change and <italic toggle="yes">Z</italic>-scores. The differential expression pattern was finally provided in the format of the violin plots in the latest DRESIS (as shown in Figure <xref rid="F7" ref-type="fig">7</xref>).</p>
        <fig position="float" id="F7">
          <label>Figure 7.</label>
          <caption>
            <p>A typical page in DRESIS that provides the disease-specific expression abundances of the key resistance molecules. The violin plot in the upper part of this diagram shows the disease-specific abundances of a key molecule, and the abundance profiles of a total of 63 disease classes are provided for each key resistance molecule. The abundance variation, <italic toggle="yes">Z</italic>-score and fold change between groups are described. Red group, key molecules expressed in disease tissue of patients; green group, key molecule expressed in normal tissue of healthy individuals.</p>
          </caption>
          <graphic xlink:href="gkac812fig7" position="float"/>
        </fig>
      </sec>
      <sec id="SEC2-4-2">
        <title>Tissue-specific expression variations of the key resistance molecules</title>
        <p>For the key resistance proteins, a benchmark (<xref rid="B106" ref-type="bibr">106</xref>) was first collected from GEO which contained the samples across 36 human tissues. Second, for a particular protein, the median of the abundances from multiple samples within the same tissue was calculated and the resulting values were scaled based on a logarithm to the base of two. Finally, bar plots were drawn to illustrate the expression variations of those key resistance proteins among various tissues. For the key resistance ncRNAs, their tissue-specific abundances were also collected. First, a benchmark (<xref rid="B105" ref-type="bibr">105</xref>) was first collected from the Genotype-Tissue Expression database which provided 7862 healthy samples across 31 human tissues. Second, for an ncRNA, the median of the RNA abundances from multiple samples of the same tissue was calculated and the resulting values were scaled based on the logarithm to the base of two. Finally, a bar plot was drawn to show the tissue-specific abundance variations of those key resistance ncRNAs among various tissues (as shown in Figure <xref rid="F8" ref-type="fig">8</xref>).</p>
        <fig position="float" id="F8">
          <label>Figure 8.</label>
          <caption>
            <p>A typical page in DRESIS that provides the tissue-specific expression abundances for key resistance molecules, which was drawn to describe the tissue-specific abundance variations of the key resistance molecules among different tissues. The corresponding expression data were retrieved from two benchmarks previously published in two reputable studies (<xref rid="B105" ref-type="bibr">105</xref>,<xref rid="B106" ref-type="bibr">106</xref>).</p>
          </caption>
          <graphic xlink:href="gkac812fig8" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec id="SEC2-5">
      <title>Standardization, access and retrieval of the DRESIS data</title>
      <p>To make the access and analysis of DRESIS data convenient for all readers, the collected raw data were carefully cleaned up and then systematically standardized. These standardizations included: (i) all diseases were standardized based on the latest International Classification of Disease that was officially released by the WHO (<xref rid="B81" ref-type="bibr">81</xref>); (ii) drugs, proteins, ncRNAs, cell lines, pathways, species and diseases in DRESIS were cross-linked to well-established databases. Second, a user-friendly interface was provided in DRESIS to conveniently browse and search data. DRESIS provides a quick search utility so that users can search the entire DRESIS textual component for drug resistance data in the main search frame or in a pull-down menu. Additionally, ‘Drug structure similarity search’ and ‘Molecule sequence similarity search’ were provided in DRESIS. Users can input the drug structure in the format of SMILES or draw structure to discover the drugs with the same or similar structures that are collected in DRESIS. In the section ‘Molecule sequence similarity search’, users can input the protein/RNA sequence in FASTA format. Finally, all drug resistance data can be viewed, accessed and downloaded from DRESIS, which is freely accessible without a login requirement by all users at: <ext-link xlink:href="https://idrblab.org/dresis/" ext-link-type="uri">https://idrblab.org/dresis/</ext-link>.</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="SEC3">
    <title>CONCLUSION AND PROSPECT</title>
    <p>In this study, a database named ‘DRESIS’ was introduced to provide comprehensive resistance information of a large number of drugs. It is unique in systematically providing, for the first time, all existing types of molecular mechanisms underlying drug resistance, extensively covering the widest range of diseases among the existing databases and explicitly describing the clinically or experimentally verified resistance data for the largest number of drugs. Since drug resistance has become an ever-increasing clinical issue, there will be an exponentially increasing amount of new drug resistance data derived from patients with different diseases in the future. So, the drug resistance data in DRESIS will be updated in a timely fashion and the webpages will be regularly improved. Furthermore, more annotation information and practical analysis tools will be added to keep pace with ongoing research. Therefore, this newly constructed database is expected to serve as a timely and valuable resource for understanding of the molecular mechanisms of drug resistance in diverse diseases, which will have great implications for the future practice of new drug discovery.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC4">
    <title>DATA AVAILABILITY</title>
    <p>All drug resistance data can be viewed, accessed and downloaded from DRESIS, which is freely accessible without a login requirement by all users at: <ext-link xlink:href="https://idrblab.org/dresis/" ext-link-type="uri">https://idrblab.org/dresis/</ext-link>.</p>
  </sec>
</body>
<back>
  <sec id="SEC5">
    <title>FUNDING</title>
    <p>Funded by Natural Science Foundation of Zhejiang Province [LR21H300001]; National Natural Science Foundation of China [U1909208 &amp; 81872798]; Leading Talent of ‘Ten Thousand Plan’ of the National High-Level Talents Special Support Plan of China; Fundamental Research Fund of Central University [2018QNA7023]; Key R&amp;D Program of Zhejiang Province [2020C03010]; Chinese ‘Double Top-Class’ Universities [181201*194232101]; Westlake Laboratory (Westlake Laboratory of Life Science &amp; Biomedicine); Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare; Alibaba Cloud; Information Tech Center of Zhejiang University.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kozic</surname><given-names>M.</given-names></string-name>, <string-name><surname>Fox</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Verma</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>Rigden</surname><given-names>D.J.</given-names></string-name></person-group><article-title>Large scale ab initio modeling of structurally uncharacterized antimicrobial peptides reveals known and novel folds</article-title>. <source>Proteins</source>. <year>2018</year>; <volume>86</volume>:<fpage>548</fpage>–<lpage>565</lpage>.<pub-id pub-id-type="pmid">29388242</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bertagnolio</surname><given-names>S.</given-names></string-name>, <string-name><surname>Jordan</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Doherty</surname><given-names>M.</given-names></string-name></person-group><article-title>HIV drug resistance</article-title>. <source>N. Engl. J. Med.</source><year>2018</year>; <volume>378</volume>:<fpage>874</fpage>.</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mullard</surname><given-names>A.</given-names></string-name></person-group><article-title>Stemming the tide of drug resistance in cancer</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2020</year>; <volume>19</volume>:<fpage>221</fpage>–<lpage>223</lpage>.<pub-id pub-id-type="pmid">32203291</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>P.</given-names></string-name>, <string-name><surname>Cross</surname><given-names>D.</given-names></string-name>, <string-name><surname>Janne</surname><given-names>P.A.</given-names></string-name></person-group><article-title>Kinase drug discovery 20 years after imatinib: progress and future directions</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2021</year>; <volume>20</volume>:<fpage>551</fpage>–<lpage>569</lpage>.<pub-id pub-id-type="pmid">34002056</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhan</surname><given-names>J.Y.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>Q.C.</given-names></string-name></person-group><article-title>Molecular dynamics investigation on the asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL</article-title>. <source>J. Mol. Graph. Model</source>. <year>2019</year>; <volume>89</volume>:<fpage>242</fpage>–<lpage>249</lpage>.<pub-id pub-id-type="pmid">30927708</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xue</surname><given-names>W.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>Molecular mechanism for the allosteric inhibition of the human serotonin transporter by antidepressant escitalopram</article-title>. <source>ACS Chem. Neurosci.</source><year>2022</year>; <volume>13</volume>:<fpage>340</fpage>–<lpage>351</lpage>.<pub-id pub-id-type="pmid">35041375</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xue</surname><given-names>W.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P.</given-names></string-name>, <string-name><surname>Tu</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>G.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder</article-title>. <source>Phys. Chem. Chem. Phys.</source><year>2018</year>; <volume>20</volume>:<fpage>6606</fpage>–<lpage>6616</lpage>.<pub-id pub-id-type="pmid">29451287</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meric-Bernstam</surname><given-names>F.</given-names></string-name>, <string-name><surname>Larkin</surname><given-names>J.</given-names></string-name>, <string-name><surname>Tabernero</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bonini</surname><given-names>C.</given-names></string-name></person-group><article-title>Enhancing anti-tumour efficacy with immunotherapy combinations</article-title>. <source>Lancet</source>. <year>2021</year>; <volume>397</volume>:<fpage>1010</fpage>–<lpage>1022</lpage>.<pub-id pub-id-type="pmid">33285141</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yahav</surname><given-names>D.</given-names></string-name>, <string-name><surname>Giske</surname><given-names>C.G.</given-names></string-name>, <string-name><surname>Gramatniece</surname><given-names>A.</given-names></string-name>, <string-name><surname>Abodakpi</surname><given-names>H.</given-names></string-name>, <string-name><surname>Tam</surname><given-names>V.H.</given-names></string-name>, <string-name><surname>Leibovici</surname><given-names>L.</given-names></string-name></person-group><article-title>New beta-lactam–beta-lactamase inhibitor combinations</article-title>. <source>Clin. Microbiol. Rev.</source><year>2020</year>; <volume>34</volume>:<fpage>115</fpage>–<lpage>120</lpage>.</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buondonno</surname><given-names>I.</given-names></string-name>, <string-name><surname>Gazzano</surname><given-names>E.</given-names></string-name>, <string-name><surname>Tavanti</surname><given-names>E.</given-names></string-name>, <string-name><surname>Chegaev</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kopecka</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fanelli</surname><given-names>M.</given-names></string-name>, <string-name><surname>Rolando</surname><given-names>B.</given-names></string-name>, <string-name><surname>Fruttero</surname><given-names>R.</given-names></string-name>, <string-name><surname>Gasco</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hattinger</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma</article-title>. <source>Cell. Mol. Life Sci.</source><year>2019</year>; <volume>76</volume>:<fpage>609</fpage>–<lpage>625</lpage>.<pub-id pub-id-type="pmid">30430199</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobrovolsky</surname><given-names>D.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>E.S.</given-names></string-name>, <string-name><surname>Morrow</surname><given-names>S.</given-names></string-name>, <string-name><surname>Leahy</surname><given-names>C.</given-names></string-name>, <string-name><surname>Faust</surname><given-names>T.</given-names></string-name>, <string-name><surname>Nowak</surname><given-names>R.P.</given-names></string-name>, <string-name><surname>Donovan</surname><given-names>K.A.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>E.S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Bruton tyrosine kinase degradation as a therapeutic strategy for cancer</article-title>. <source>Blood</source>. <year>2019</year>; <volume>133</volume>:<fpage>952</fpage>–<lpage>961</lpage>.<pub-id pub-id-type="pmid">30545835</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Su</surname><given-names>R.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wei</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zou</surname><given-names>Q.</given-names></string-name></person-group><article-title>Deep-Resp-Forest: a deep forest model to predict anti-cancer drug response</article-title>. <source>Methods</source>. <year>2019</year>; <volume>166</volume>:<fpage>91</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">30772464</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname><given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>X.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Anti-CD24 antibody–nitric oxide conjugate selectively and potently suppresses hepatic carcinoma</article-title>. <source>Cancer Res.</source><year>2019</year>; <volume>79</volume>:<fpage>3395</fpage>–<lpage>3405</lpage>.<pub-id pub-id-type="pmid">30918001</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kong</surname><given-names>X.</given-names></string-name>, <string-name><surname>Pan</surname><given-names>P.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hou</surname><given-names>T.</given-names></string-name></person-group><article-title>Drug discovery targeting anaplastic lymphoma kinase (ALK)</article-title>. <source>J. Med. Chem.</source><year>2019</year>; <volume>62</volume>:<fpage>10927</fpage>–<lpage>10954</lpage>.<pub-id pub-id-type="pmid">31419130</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>R.G.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.X.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>Q.C.</given-names></string-name></person-group><article-title>Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses</article-title>. <source>Phys. Chem. Chem. Phys.</source><year>2020</year>; <volume>22</volume>:<fpage>4464</fpage>–<lpage>4480</lpage>.<pub-id pub-id-type="pmid">32057044</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname><given-names>T.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>T.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Fei</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Z.</given-names></string-name></person-group><article-title>General strategy for integrated bioorthogonal prodrugs: Pt(II)-triggered depropargylation enables controllable drug activation in vivo</article-title>. <source>J. Med. Chem.</source><year>2020</year>; <volume>63</volume>:<fpage>13899</fpage>–<lpage>13912</lpage>.<pub-id pub-id-type="pmid">33141588</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davar</surname><given-names>D.</given-names></string-name>, <string-name><surname>Dzutsev</surname><given-names>A.K.</given-names></string-name>, <string-name><surname>McCulloch</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Rodrigues</surname><given-names>R.R.</given-names></string-name>, <string-name><surname>Chauvin</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Deblasio</surname><given-names>R.N.</given-names></string-name>, <string-name><surname>Menna</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ding</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Pagliano</surname><given-names>O.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients</article-title>. <source>Science</source>. <year>2021</year>; <volume>371</volume>:<fpage>595</fpage>–<lpage>602</lpage>.<pub-id pub-id-type="pmid">33542131</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xavier</surname><given-names>C.P.R.</given-names></string-name>, <string-name><surname>Belisario</surname><given-names>D.C.</given-names></string-name>, <string-name><surname>Rebelo</surname><given-names>R.</given-names></string-name>, <string-name><surname>Assaraf</surname><given-names>Y.G.</given-names></string-name>, <string-name><surname>Giovannetti</surname><given-names>E.</given-names></string-name>, <string-name><surname>Kopecka</surname><given-names>J.</given-names></string-name>, <string-name><surname>Vasconcelos</surname><given-names>M.H.</given-names></string-name></person-group><article-title>The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells</article-title>. <source>Drug Resist. Updat.</source><year>2022</year>; <volume>62</volume>:<fpage>100833</fpage>.<pub-id pub-id-type="pmid">35429792</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alexa-Stratulat</surname><given-names>T.</given-names></string-name>, <string-name><surname>Pesic</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gasparovic</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Trougakos</surname><given-names>I.P.</given-names></string-name>, <string-name><surname>Riganti</surname><given-names>C</given-names></string-name></person-group><article-title>What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg</article-title>. <source>Drug Resist. Updat.</source><year>2019</year>; <volume>46</volume>:<fpage>100643</fpage>.<pub-id pub-id-type="pmid">31493711</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yin</surname><given-names>J.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>W.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xin</surname><given-names>W.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>VARIDT 2.0: structural variability of drug transporter</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1417</fpage>–<lpage>D1431</lpage>.<pub-id pub-id-type="pmid">34747471</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xue</surname><given-names>W.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>G.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>What contributes to serotonin–norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation</article-title>. <source>ACS Chem. Neurosci.</source><year>2018</year>; <volume>9</volume>:<fpage>1128</fpage>–<lpage>1140</lpage>.<pub-id pub-id-type="pmid">29300091</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Yin</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name><etal>et al</etal>.</person-group><article-title>ConSIG: consistent discovery of molecular signature from OMIC data</article-title>. <source>Brief. Bioinform</source>. <year>2022</year>; <volume>23</volume>:<fpage>bbac253</fpage>.<pub-id pub-id-type="pmid">35758241</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ward</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Fawell</surname><given-names>S.</given-names></string-name>, <string-name><surname>Floc’h</surname><given-names>N.</given-names></string-name>, <string-name><surname>Flemington</surname><given-names>V.</given-names></string-name>, <string-name><surname>McKerrecher</surname><given-names>D.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>P.D.</given-names></string-name></person-group><article-title>Challenges and opportunities in cancer drug resistance</article-title>. <source>Chem. Rev.</source><year>2021</year>; <volume>121</volume>:<fpage>3297</fpage>–<lpage>3351</lpage>.<pub-id pub-id-type="pmid">32692162</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>W.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Optimization of metabolomic data processing using NOREVA</article-title>. <source>Nat. Protoc.</source><year>2022</year>; <volume>17</volume>:<fpage>129</fpage>–<lpage>151</lpage>.<pub-id pub-id-type="pmid">34952956</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zappasodi</surname><given-names>R.</given-names></string-name>, <string-name><surname>Sirard</surname><given-names>C.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Budhu</surname><given-names>S.</given-names></string-name>, <string-name><surname>Abu-Akeel</surname><given-names>M.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhong</surname><given-names>H.</given-names></string-name>, <string-name><surname>Newman</surname><given-names>W.</given-names></string-name>, <string-name><surname>Qi</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Rational design of anti-GITR-based combination immunotherapy</article-title>. <source>Nat. Med.</source><year>2019</year>; <volume>25</volume>:<fpage>759</fpage>–<lpage>766</lpage>.<pub-id pub-id-type="pmid">31036879</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lian</surname><given-names>X.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>Pharmacometabonomics: data processing and statistical analysis</article-title>. <source>Brief. Bioinform.</source><year>2021</year>; <volume>22</volume>:<fpage>bbab138</fpage>.<pub-id pub-id-type="pmid">33866355</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sousa</surname><given-names>D.</given-names></string-name>, <string-name><surname>Lima</surname><given-names>R.T.</given-names></string-name>, <string-name><surname>Lopes-Rodrigues</surname><given-names>V.</given-names></string-name>, <string-name><surname>Gonzalez</surname><given-names>E.</given-names></string-name>, <string-name><surname>Royo</surname><given-names>F.</given-names></string-name>, <string-name><surname>Xavier</surname><given-names>C.P.R.</given-names></string-name>, <string-name><surname>Falcon-Perez</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Vasconcelos</surname><given-names>M.H.</given-names></string-name></person-group><article-title>Different ability of multidrug-resistant and -sensitive counterpart cells to release and capture extracellular vesicles</article-title>. <source>Cells</source>. <year>2021</year>; <volume>10</volume>:<fpage>2886</fpage>.<pub-id pub-id-type="pmid">34831110</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>G.</given-names></string-name>, <string-name><surname>Tu</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xue</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>Exploring the binding mechanism of metabotropic glutamate receptor 5 negative allosteric modulators in clinical trials by molecular dynamics simulations</article-title>. <source>ACS Chem. Neurosci.</source><year>2018</year>; <volume>9</volume>:<fpage>1492</fpage>–<lpage>1502</lpage>.<pub-id pub-id-type="pmid">29522307</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hughes</surname><given-names>D.</given-names></string-name>, <string-name><surname>Andersson</surname><given-names>D.I.</given-names></string-name></person-group><article-title>Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms</article-title>. <source>Nat. Rev. Genet.</source><year>2015</year>; <volume>16</volume>:<fpage>459</fpage>–<lpage>471</lpage>.<pub-id pub-id-type="pmid">26149714</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ding</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zou</surname><given-names>Q.</given-names></string-name></person-group><article-title>Identification of drug–target interactions via multiple kernel-based triple collaborative matrix factorization</article-title>. <source>Brief. Bioinform.</source><year>2022</year>; <volume>23</volume>:<fpage>bbab582</fpage>.<pub-id pub-id-type="pmid">35134117</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>W.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>R.</given-names></string-name>, <string-name><surname>Marquez-Lago</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Leier</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>T.</given-names></string-name>, <string-name><surname>Torres</surname><given-names>V.</given-names></string-name>, <string-name><surname>Hay</surname><given-names>I.</given-names></string-name><etal>et al</etal>.</person-group><article-title>BastionHub: a universal platform for integrating and analyzing substrates secreted by Gram-negative bacteria</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D651</fpage>–<lpage>D659</lpage>.<pub-id pub-id-type="pmid">33084862</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>Y.H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.X.</given-names></string-name>, <string-name><surname>Hong</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.X.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.C.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Xue</surname><given-names>W.W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs</article-title>. <source>Brief. Bioinform.</source><year>2020</year>; <volume>21</volume>:<fpage>649</fpage>–<lpage>662</lpage>.<pub-id pub-id-type="pmid">30689717</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rodrik-Outmezguine</surname><given-names>V.S.</given-names></string-name>, <string-name><surname>Okaniwa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Novotny</surname><given-names>C.J.</given-names></string-name>, <string-name><surname>McWhirter</surname><given-names>C.</given-names></string-name>, <string-name><surname>Banaji</surname><given-names>A.</given-names></string-name>, <string-name><surname>Won</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>W.</given-names></string-name>, <string-name><surname>Berger</surname><given-names>M.</given-names></string-name>, <string-name><surname>de Stanchina</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor</article-title>. <source>Nature</source>. <year>2016</year>; <volume>534</volume>:<fpage>272</fpage>–<lpage>276</lpage>.<pub-id pub-id-type="pmid">27279227</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Leier</surname><given-names>A.</given-names></string-name>, <string-name><surname>Xiang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>H.H.</given-names></string-name>, <string-name><surname>Marquez Lago</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Song</surname><given-names>J.</given-names></string-name></person-group><article-title>Comprehensive assessment of machine learning-based methods for predicting antimicrobial peptides</article-title>. <source>Brief. Bioinform.</source><year>2021</year>; <volume>22</volume>:<fpage>bbab083</fpage>.<pub-id pub-id-type="pmid">33774670</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holohan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Van Schaeybroeck</surname><given-names>S.</given-names></string-name>, <string-name><surname>Longley</surname><given-names>D.B.</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>P.G.</given-names></string-name></person-group><article-title>Cancer drug resistance: an evolving paradigm</article-title>. <source>Nat. Rev. Cancer</source>. <year>2013</year>; <volume>13</volume>:<fpage>714</fpage>–<lpage>726</lpage>.<pub-id pub-id-type="pmid">24060863</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meric-Bernstam</surname><given-names>F.</given-names></string-name>, <string-name><surname>Hurwitz</surname><given-names>H.</given-names></string-name>, <string-name><surname>Raghav</surname><given-names>K.P.S.</given-names></string-name>, <string-name><surname>McWilliams</surname><given-names>R.R.</given-names></string-name>, <string-name><surname>Fakih</surname><given-names>M.</given-names></string-name>, <string-name><surname>VanderWalde</surname><given-names>A.</given-names></string-name>, <string-name><surname>Swanton</surname><given-names>C.</given-names></string-name>, <string-name><surname>Kurzrock</surname><given-names>R.</given-names></string-name>, <string-name><surname>Burris</surname><given-names>H.</given-names></string-name>, <string-name><surname>Sweeney</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study</article-title>. <source>Lancet Oncol.</source><year>2019</year>; <volume>20</volume>:<fpage>518</fpage>–<lpage>530</lpage>.<pub-id pub-id-type="pmid">30857956</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abd-Ellatef</surname><given-names>G.E.F.</given-names></string-name>, <string-name><surname>Gazzano</surname><given-names>E.</given-names></string-name>, <string-name><surname>El-Desoky</surname><given-names>A.H.</given-names></string-name>, <string-name><surname>Hamed</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Kopecka</surname><given-names>J.</given-names></string-name>, <string-name><surname>Belisario</surname><given-names>D.C.</given-names></string-name>, <string-name><surname>Costamagna</surname><given-names>C.</given-names></string-name>, <string-name><surname>S Marie</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Fahmy</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>Abdel-Hamid</surname><given-names>A.Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein</article-title>. <source>Pharmacol. Res.</source><year>2022</year>; <volume>175</volume>:<fpage>105975</fpage>.<pub-id pub-id-type="pmid">34785319</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yin</surname><given-names>J.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>POSREG: proteomic signature discovered by simultaneously optimizing its reproducibility and generalizability</article-title>. <source>Brief. Bioinform</source>. <year>2022</year>; <volume>23</volume>:<fpage>bbac040</fpage>.<pub-id pub-id-type="pmid">35183059</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robey</surname><given-names>R.W.</given-names></string-name>, <string-name><surname>Pluchino</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>Hall</surname><given-names>M.D.</given-names></string-name>, <string-name><surname>Fojo</surname><given-names>A.T.</given-names></string-name>, <string-name><surname>Bates</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Gottesman</surname><given-names>M.M.</given-names></string-name></person-group><article-title>Revisiting the role of ABC transporters in multidrug-resistant cancer</article-title>. <source>Nat. Rev. Cancer</source>. <year>2018</year>; <volume>18</volume>:<fpage>452</fpage>–<lpage>464</lpage>.<pub-id pub-id-type="pmid">29643473</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bush</surname><given-names>K.</given-names></string-name>, <string-name><surname>Bradford</surname><given-names>P.A.</given-names></string-name></person-group><article-title>Epidemiology of beta-lactamase-producing pathogens</article-title>. <source>Clin. Microbiol. Rev.</source><year>2020</year>; <volume>33</volume>:<fpage>e00047</fpage>–<lpage>e00019</lpage>.<pub-id pub-id-type="pmid">32102899</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>X.</given-names></string-name>, <string-name><surname>Mou</surname><given-names>M.</given-names></string-name>, <string-name><surname>Amahong</surname><given-names>K.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>REGLIV: molecular regulation data of diverse living systems facilitating current multiomics research</article-title>. <source>Comput. Biol. Med.</source><year>2022</year>; <volume>148</volume>:<fpage>105825</fpage>.<pub-id pub-id-type="pmid">35872412</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>X.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>L.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>S.</given-names></string-name></person-group><article-title>Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin</article-title>. <source>Sci. Transl. Med.</source><year>2016</year>; <volume>8</volume>:<fpage>348ra397</fpage>.</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Amahong</surname><given-names>K.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>RNA–RNA interactions between SARS-CoV-2 and host benefit viral development and evolution during COVID-19 infection</article-title>. <source>Brief. Bioinform.</source><year>2021</year>; <volume>23</volume>:<fpage>bbab397</fpage>.</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ying</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Hong</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.C.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>F.Y.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>G.X.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>X.J.</given-names></string-name>, <string-name><surname>Lou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>Y.</given-names></string-name><etal>et al</etal>.</person-group><article-title>How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from trichostatin A enantiomers based on molecular dynamics</article-title>. <source>ACS Chem. Neurosci.</source><year>2019</year>; <volume>10</volume>:<fpage>2467</fpage>–<lpage>2480</lpage>.<pub-id pub-id-type="pmid">30784262</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Narayanan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cai</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Assaraf</surname><given-names>Y.G.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>H.Q.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Wei</surname><given-names>L.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Ashby</surname><given-names>C.R.</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Chen</surname><given-names>Z.S</given-names></string-name></person-group><article-title>Targeting the ubiquitin–proteasome pathway to overcome anti-cancer drug resistance</article-title>. <source>Drug Resist. Updat.</source><year>2020</year>; <volume>48</volume>:<fpage>100663</fpage>.<pub-id pub-id-type="pmid">31785545</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ye</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Z.</given-names></string-name></person-group><article-title>Protein S-nitrosation: biochemistry, identification, molecular mechanisms, and therapeutic applications</article-title>. <source>J. Med. Chem.</source><year>2022</year>; <volume>65</volume>:<fpage>5902</fpage>–<lpage>5925</lpage>.<pub-id pub-id-type="pmid">35412827</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maacha</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bhat</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Jimenez</surname><given-names>L.</given-names></string-name>, <string-name><surname>Raza</surname><given-names>A.</given-names></string-name>, <string-name><surname>Haris</surname><given-names>M.</given-names></string-name>, <string-name><surname>Uddin</surname><given-names>S.</given-names></string-name>, <string-name><surname>Grivel</surname><given-names>J.C.</given-names></string-name></person-group><article-title>Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance</article-title>. <source>Mol. Cancer</source>. <year>2019</year>; <volume>18</volume>:<fpage>55</fpage>.<pub-id pub-id-type="pmid">30925923</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xavier</surname><given-names>C.P.R.</given-names></string-name>, <string-name><surname>Caires</surname><given-names>H.R.</given-names></string-name>, <string-name><surname>Barbosa</surname><given-names>M.A.G.</given-names></string-name>, <string-name><surname>Bergantim</surname><given-names>R.</given-names></string-name>, <string-name><surname>Guimaraes</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Vasconcelos</surname><given-names>M.H.</given-names></string-name></person-group><article-title>The role of extracellular vesicles in the hallmarks of cancer and drug resistance</article-title>. <source>Cells</source>. <year>2020</year>; <volume>9</volume>:<fpage>1141</fpage>.<pub-id pub-id-type="pmid">32384712</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larsson</surname><given-names>D.G.J.</given-names></string-name>, <string-name><surname>Flach</surname><given-names>C.F.</given-names></string-name></person-group><article-title>Antibiotic resistance in the environment</article-title>. <source>Nat. Rev. Microbiol.</source><year>2022</year>; <volume>20</volume>:<fpage>257</fpage>–<lpage>269</lpage>.<pub-id pub-id-type="pmid">34737424</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peixoto da Silva</surname><given-names>S.</given-names></string-name>, <string-name><surname>Caires</surname><given-names>H.R.</given-names></string-name>, <string-name><surname>Bergantim</surname><given-names>R.</given-names></string-name>, <string-name><surname>Guimaraes</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Vasconcelos</surname><given-names>M.H.</given-names></string-name></person-group><article-title>miRNAs mediated drug resistance in hematological malignancies</article-title>. <source>Semin. Cancer Biol.</source><year>2022</year>; <volume>83</volume>:<fpage>283</fpage>–<lpage>302</lpage>.<pub-id pub-id-type="pmid">33757848</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gottesman</surname><given-names>M.M.</given-names></string-name>, <string-name><surname>Lavi</surname><given-names>O.</given-names></string-name>, <string-name><surname>Hall</surname><given-names>M.D.</given-names></string-name>, <string-name><surname>Gillet</surname><given-names>J.P.</given-names></string-name></person-group><article-title>Toward a better understanding of the complexity of cancer drug resistance</article-title>. <source>Annu. Rev. Pharmacol. Toxicol.</source><year>2016</year>; <volume>56</volume>:<fpage>85</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">26514196</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kurt Yilmaz</surname><given-names>N.</given-names></string-name>, <string-name><surname>Schiffer</surname><given-names>C.A</given-names></string-name></person-group><article-title>Introduction: drug resistance</article-title>. <source>Chem. Rev.</source><year>2021</year>; <volume>121</volume>:<fpage>3235</fpage>–<lpage>3237</lpage>.<pub-id pub-id-type="pmid">33757288</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Munita</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Arias</surname><given-names>C.A.</given-names></string-name></person-group><article-title>Mechanisms of antibiotic resistance</article-title>. <source>Microbiol. Spectr</source>. <year>2016</year>; <volume>4</volume>:<fpage>10</fpage>.</mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Milosevic</surname><given-names>V.</given-names></string-name>, <string-name><surname>Kopecka</surname><given-names>J.</given-names></string-name>, <string-name><surname>Salaroglio</surname><given-names>I.C.</given-names></string-name>, <string-name><surname>Libener</surname><given-names>R.</given-names></string-name>, <string-name><surname>Napoli</surname><given-names>F.</given-names></string-name>, <string-name><surname>Izzo</surname><given-names>S.</given-names></string-name>, <string-name><surname>Orecchia</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ananthanarayanan</surname><given-names>P.</given-names></string-name>, <string-name><surname>Bironzo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Grosso</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Wnt/IL-1beta/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5</article-title>. <source>Int. J. Cancer</source>. <year>2020</year>; <volume>146</volume>:<fpage>192</fpage>–<lpage>207</lpage>.<pub-id pub-id-type="pmid">31107974</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tolios</surname><given-names>A.</given-names></string-name>, <string-name><surname>De Las Rivas</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hovig</surname><given-names>E.</given-names></string-name>, <string-name><surname>Trouillas</surname><given-names>P.</given-names></string-name>, <string-name><surname>Scorilas</surname><given-names>A.</given-names></string-name>, <string-name><surname>Mohr</surname><given-names>T.</given-names></string-name></person-group><article-title>Computational approaches in cancer multidrug resistance research: identification of potential biomarkers, drug targets and drug–target interactions</article-title>. <source>Drug Resist. Updat.</source><year>2020</year>; <volume>48</volume>:<fpage>100662</fpage>.<pub-id pub-id-type="pmid">31927437</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spohn</surname><given-names>R.</given-names></string-name>, <string-name><surname>Daruka</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lazar</surname><given-names>V.</given-names></string-name>, <string-name><surname>Martins</surname><given-names>A.</given-names></string-name>, <string-name><surname>Vidovics</surname><given-names>F.</given-names></string-name>, <string-name><surname>Grezal</surname><given-names>G.</given-names></string-name>, <string-name><surname>Mehi</surname><given-names>O.</given-names></string-name>, <string-name><surname>Kintses</surname><given-names>B.</given-names></string-name>, <string-name><surname>Szamel</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jangir</surname><given-names>P.K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance</article-title>. <source>Nat. Commun.</source><year>2019</year>; <volume>10</volume>:<fpage>4538</fpage>.<pub-id pub-id-type="pmid">31586049</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wijdeven</surname><given-names>R.H.</given-names></string-name>, <string-name><surname>Pang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Assaraf</surname><given-names>Y.G.</given-names></string-name>, <string-name><surname>Neefjes</surname><given-names>J.</given-names></string-name></person-group><article-title>Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics</article-title>. <source>Drug Resist. Updat.</source><year>2016</year>; <volume>28</volume>:<fpage>65</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">27620955</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname><given-names>R.</given-names></string-name>, <string-name><surname>Chaudhary</surname><given-names>K.</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>S.</given-names></string-name>, <string-name><surname>Singh</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gautam</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kapoor</surname><given-names>P.</given-names></string-name>, <string-name><surname>Raghava</surname><given-names>G.P.</given-names></string-name></person-group><article-title>CancerDR: cancer drug resistance database</article-title>. <source>Sci. Rep.</source><year>2013</year>; <volume>3</volume>:<fpage>1445</fpage>.<pub-id pub-id-type="pmid">23486013</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname><given-names>R.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Jia</surname><given-names>P.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Z.</given-names></string-name></person-group><article-title>KinaseMD: kinase mutations and drug response database</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D552</fpage>–<lpage>D561</lpage>.<pub-id pub-id-type="pmid">33137204</pub-id></mixed-citation>
    </ref>
    <ref id="B60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>C.</given-names></string-name></person-group><article-title>The HIV positive selection mutation database</article-title>. <source>Nucleic Acids Res.</source><year>2007</year>; <volume>35</volume>:<fpage>D371</fpage>–<lpage>D375</lpage>.<pub-id pub-id-type="pmid">17108357</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <label>61.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hayer</surname><given-names>J.</given-names></string-name>, <string-name><surname>Jadeau</surname><given-names>F.</given-names></string-name>, <string-name><surname>Deleage</surname><given-names>G.</given-names></string-name>, <string-name><surname>Kay</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zoulim</surname><given-names>F.</given-names></string-name>, <string-name><surname>Combet</surname><given-names>C.</given-names></string-name></person-group><article-title>HBVdb: a knowledge database for hepatitis B virus</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>D566</fpage>–<lpage>D570</lpage>.<pub-id pub-id-type="pmid">23125365</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <label>62.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alcock</surname><given-names>B.P.</given-names></string-name>, <string-name><surname>Raphenya</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Lau</surname><given-names>T.T.Y.</given-names></string-name>, <string-name><surname>Tsang</surname><given-names>K.K.</given-names></string-name>, <string-name><surname>Bouchard</surname><given-names>M.</given-names></string-name>, <string-name><surname>Edalatmand</surname><given-names>A.</given-names></string-name>, <string-name><surname>Huynh</surname><given-names>W.</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>A.V.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D517</fpage>–<lpage>D525</lpage>.<pub-id pub-id-type="pmid">31665441</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <label>63.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doster</surname><given-names>E.</given-names></string-name>, <string-name><surname>Lakin</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Dean</surname><given-names>C.J.</given-names></string-name>, <string-name><surname>Wolfe</surname><given-names>C.</given-names></string-name>, <string-name><surname>Young</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Boucher</surname><given-names>C.</given-names></string-name>, <string-name><surname>Belk</surname><given-names>K.E.</given-names></string-name>, <string-name><surname>Noyes</surname><given-names>N.R.</given-names></string-name>, <string-name><surname>Morley</surname><given-names>P.S.</given-names></string-name></person-group><article-title>MEGARes 2.0: a database for classification of antimicrobial drug, biocide and metal resistance determinants in metagenomic sequence data</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D561</fpage>–<lpage>D569</lpage>.<pub-id pub-id-type="pmid">31722416</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <label>64.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nash</surname><given-names>A.</given-names></string-name>, <string-name><surname>Sewell</surname><given-names>T.</given-names></string-name>, <string-name><surname>Farrer</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Abdolrasouli</surname><given-names>A.</given-names></string-name>, <string-name><surname>Shelton</surname><given-names>J.M.G.</given-names></string-name>, <string-name><surname>Fisher</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Rhodes</surname><given-names>J.</given-names></string-name></person-group><article-title>MARDy: mycology antifungal resistance database</article-title>. <source>Bioinformatics</source>. <year>2018</year>; <volume>34</volume>:<fpage>3233</fpage>–<lpage>3234</lpage>.<pub-id pub-id-type="pmid">29897419</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <label>65.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>A.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Lei</surname><given-names>J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Leng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Li</surname><given-names>T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>LncTarD: a manually-curated database of experimentally-supported functional lncRNA–target regulations in human diseases</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D118</fpage>–<lpage>D126</lpage>.<pub-id pub-id-type="pmid">31713618</pub-id></mixed-citation>
    </ref>
    <ref id="B66">
      <label>66.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ji</surname><given-names>B.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>G.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>R.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>P.</given-names></string-name>, <string-name><surname>Ren</surname><given-names>J.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>EVLncRNAs 2.0: an updated database of manually curated functional long non-coding RNAs validated by low-throughput experiments</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D86</fpage>–<lpage>D91</lpage>.<pub-id pub-id-type="pmid">33221906</pub-id></mixed-citation>
    </ref>
    <ref id="B67">
      <label>67.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dai</surname><given-names>E.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>X.</given-names></string-name>, <string-name><surname>Song</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>D.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>L.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Ling</surname><given-names>H.</given-names></string-name></person-group><article-title>MycoResistance: a curated resource of drug resistance molecules in mycobacteria</article-title>. <source>Database</source>. <year>2019</year>; <volume>2019</volume>:<fpage>baz074</fpage>.<pub-id pub-id-type="pmid">31290951</pub-id></mixed-citation>
    </ref>
    <ref id="B68">
      <label>68.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chernyaeva</surname><given-names>E.N.</given-names></string-name>, <string-name><surname>Shulgina</surname><given-names>M.V.</given-names></string-name>, <string-name><surname>Rotkevich</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Dobrynin</surname><given-names>P.V.</given-names></string-name>, <string-name><surname>Simonov</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Shitikov</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Ischenko</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Karpova</surname><given-names>I.Y.</given-names></string-name>, <string-name><surname>Kostryukova</surname><given-names>E.S.</given-names></string-name>, <string-name><surname>Ilina</surname><given-names>E.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genome-wide <italic toggle="yes">Mycobacterium tuberculosis</italic> variation (GMTV) database: a new tool for integrating sequence variations and epidemiology</article-title>. <source>BMC Genomics</source>. <year>2014</year>; <volume>15</volume>:<fpage>308</fpage>.<pub-id pub-id-type="pmid">24767249</pub-id></mixed-citation>
    </ref>
    <ref id="B69">
      <label>69.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tate</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Bamford</surname><given-names>S.</given-names></string-name>, <string-name><surname>Jubb</surname><given-names>H.C.</given-names></string-name>, <string-name><surname>Sondka</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Beare</surname><given-names>D.M.</given-names></string-name>, <string-name><surname>Bindal</surname><given-names>N.</given-names></string-name>, <string-name><surname>Boutselakis</surname><given-names>H.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>C.G.</given-names></string-name>, <string-name><surname>Creatore</surname><given-names>C.</given-names></string-name>, <string-name><surname>Dawson</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>COSMIC: the catalogue of somatic mutations in cancer</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D941</fpage>–<lpage>D947</lpage>.<pub-id pub-id-type="pmid">30371878</pub-id></mixed-citation>
    </ref>
    <ref id="B70">
      <label>70.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Soares</surname><given-names>J.</given-names></string-name>, <string-name><surname>Greninger</surname><given-names>P.</given-names></string-name>, <string-name><surname>Edelman</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Lightfoot</surname><given-names>H.</given-names></string-name>, <string-name><surname>Forbes</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bindal</surname><given-names>N.</given-names></string-name>, <string-name><surname>Beare</surname><given-names>D.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>I.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>D955</fpage>–<lpage>D961</lpage>.<pub-id pub-id-type="pmid">23180760</pub-id></mixed-citation>
    </ref>
    <ref id="B71">
      <label>71.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Kong</surname><given-names>X.</given-names></string-name>, <string-name><surname>He</surname><given-names>M.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1184</fpage>–<lpage>D1199</lpage>.<pub-id pub-id-type="pmid">34570230</pub-id></mixed-citation>
    </ref>
    <ref id="B72">
      <label>72.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pearson</surname><given-names>E.R.</given-names></string-name></person-group><article-title>Type 2 diabetes: a multifaceted disease</article-title>. <source>Diabetologia</source>. <year>2019</year>; <volume>62</volume>:<fpage>1107</fpage>–<lpage>1112</lpage>.<pub-id pub-id-type="pmid">31161345</pub-id></mixed-citation>
    </ref>
    <ref id="B73">
      <label>73.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>K.</given-names></string-name>, <string-name><surname>Longo</surname><given-names>L.</given-names></string-name>, <string-name><surname>Narita</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Cascella</surname><given-names>N.</given-names></string-name>, <string-name><surname>Nucifora</surname><given-names>F.C.</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Coughlin</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Nestadt</surname><given-names>G.</given-names></string-name>, <string-name><surname>Sedlak</surname><given-names>T.W.</given-names></string-name>, <string-name><surname>Mihaljevic</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name><etal>et al</etal>.</person-group><article-title>A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance</article-title>. <source>Mol. Psychiatry</source>. <year>2022</year>; <volume>27</volume>:<fpage>1184</fpage>–<lpage>1191</lpage>.<pub-id pub-id-type="pmid">34642460</pub-id></mixed-citation>
    </ref>
    <ref id="B74">
      <label>74.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Fan</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>T.</given-names></string-name></person-group><article-title>Cellular plasticity and drug resistance in sarcoma</article-title>. <source>Life Sci.</source><year>2020</year>; <volume>263</volume>:<fpage>118589</fpage>.<pub-id pub-id-type="pmid">33069737</pub-id></mixed-citation>
    </ref>
    <ref id="B75">
      <label>75.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Samur</surname><given-names>M.K.</given-names></string-name>, <string-name><surname>Fulciniti</surname><given-names>M.</given-names></string-name>, <string-name><surname>Aktas Samur</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bazarbachi</surname><given-names>A.H.</given-names></string-name>, <string-name><surname>Tai</surname><given-names>Y.T.</given-names></string-name>, <string-name><surname>Prabhala</surname><given-names>R.</given-names></string-name>, <string-name><surname>Alonso</surname><given-names>A.</given-names></string-name>, <string-name><surname>Sperling</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>T.</given-names></string-name>, <string-name><surname>Petrocca</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>868</fpage>.<pub-id pub-id-type="pmid">33558511</pub-id></mixed-citation>
    </ref>
    <ref id="B76">
      <label>76.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>Q.C.</given-names></string-name></person-group><article-title>In silico analysis revealed a unique binding but ineffective mode of amantadine to influenza virus B M2 channel</article-title>. <source>J. Phys. Chem. Lett.</source><year>2021</year>; <volume>12</volume>:<fpage>1169</fpage>–<lpage>1174</lpage>.<pub-id pub-id-type="pmid">33480694</pub-id></mixed-citation>
    </ref>
    <ref id="B77">
      <label>77.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tse</surname><given-names>T.</given-names></string-name>, <string-name><surname>Fain</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>Zarin</surname><given-names>D.A.</given-names></string-name></person-group><article-title>How to avoid common problems when using clinicaltrials.gov in research: 10 issues to consider</article-title>. <source>BMJ</source>. <year>2018</year>; <volume>361</volume>:<fpage>k1452</fpage>.<pub-id pub-id-type="pmid">29802130</pub-id></mixed-citation>
    </ref>
    <ref id="B78">
      <label>78.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Lian</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name></person-group><article-title>Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1398</fpage>–<lpage>D1407</lpage>.<pub-id pub-id-type="pmid">34718717</pub-id></mixed-citation>
    </ref>
    <ref id="B79">
      <label>79.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the drugbank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B80">
      <label>80.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DeVita</surname><given-names>V.T.</given-names></string-name>, <string-name><surname>Chu</surname><given-names>E.</given-names></string-name></person-group><article-title>A history of cancer chemotherapy</article-title>. <source>Cancer Res.</source><year>2008</year>; <volume>68</volume>:<fpage>8643</fpage>–<lpage>8653</lpage>.<pub-id pub-id-type="pmid">18974103</pub-id></mixed-citation>
    </ref>
    <ref id="B81">
      <label>81.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>The</surname><given-names>Lancet.</given-names></string-name></person-group><article-title>ICD-11</article-title>. <source>Lancet</source>. <year>2019</year>; <volume>393</volume>:<fpage>2275</fpage>.<pub-id pub-id-type="pmid">31180012</pub-id></mixed-citation>
    </ref>
    <ref id="B82">
      <label>82.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Gindulyte</surname><given-names>A.</given-names></string-name>, <string-name><surname>He</surname><given-names>J.</given-names></string-name>, <string-name><surname>He</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Shoemaker</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Thiessen</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PubChem in 2021: new data content and improved web interfaces</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D1388</fpage>–<lpage>D1395</lpage>.<pub-id pub-id-type="pmid">33151290</pub-id></mixed-citation>
    </ref>
    <ref id="B83">
      <label>83.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>R.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ren</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>Y.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D1031</fpage>–<lpage>D1041</lpage>.<pub-id pub-id-type="pmid">31691823</pub-id></mixed-citation>
    </ref>
    <ref id="B84">
      <label>84.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yin</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>W.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Hong</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>VARIDT 1.0: variability of drug transporter database</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D1042</fpage>–<lpage>D1050</lpage>.<pub-id pub-id-type="pmid">31495872</pub-id></mixed-citation>
    </ref>
    <ref id="B85">
      <label>85.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yin</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Mou</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Xue</surname><given-names>J.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>J.</given-names></string-name>, <string-name><surname>He</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>INTEDE: interactome of drug-metabolizing enzymes</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D1233</fpage>–<lpage>D1243</lpage>.<pub-id pub-id-type="pmid">33045737</pub-id></mixed-citation>
    </ref>
    <ref id="B86">
      <label>86.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vasan</surname><given-names>N.</given-names></string-name>, <string-name><surname>Baselga</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hyman</surname><given-names>D.M.</given-names></string-name></person-group><article-title>A view on drug resistance in cancer</article-title>. <source>Nature</source>. <year>2019</year>; <volume>575</volume>:<fpage>299</fpage>–<lpage>309</lpage>.<pub-id pub-id-type="pmid">31723286</pub-id></mixed-citation>
    </ref>
    <ref id="B87">
      <label>87.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kopecka</surname><given-names>J.</given-names></string-name>, <string-name><surname>Trouillas</surname><given-names>P.</given-names></string-name>, <string-name><surname>Gasparovic</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Gazzano</surname><given-names>E.</given-names></string-name>, <string-name><surname>Assaraf</surname><given-names>Y.G.</given-names></string-name>, <string-name><surname>Riganti</surname><given-names>C.</given-names></string-name></person-group><article-title>Phospholipids and cholesterol: inducers of cancer multidrug resistance and therapeutic targets</article-title>. <source>Drug Resist. Updat.</source><year>2020</year>; <volume>49</volume>:<fpage>100670</fpage>.<pub-id pub-id-type="pmid">31846838</pub-id></mixed-citation>
    </ref>
    <ref id="B88">
      <label>88.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zeng</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>G.</given-names></string-name>, <string-name><surname>Bing</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zou</surname><given-names>Q.</given-names></string-name></person-group><article-title>Prediction of potential disease-associated microRNAs by using neural networks</article-title>. <source>Mol. Ther. Nucleic Acids</source>. <year>2019</year>; <volume>16</volume>:<fpage>566</fpage>–<lpage>575</lpage>.<pub-id pub-id-type="pmid">31077936</pub-id></mixed-citation>
    </ref>
    <ref id="B89">
      <label>89.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ji</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Z.</given-names></string-name></person-group><article-title>Novel ligustrazine-based analogs of piperlongumine potently suppress proliferation and metastasis of colorectal cancer cells in vitro and in vivo</article-title>. <source>J. Med. Chem.</source><year>2018</year>; <volume>61</volume>:<fpage>1821</fpage>–<lpage>1832</lpage>.<pub-id pub-id-type="pmid">29424539</pub-id></mixed-citation>
    </ref>
    <ref id="B90">
      <label>90.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jamialahmadi</surname><given-names>K.</given-names></string-name>, <string-name><surname>Zahedipour</surname><given-names>F.</given-names></string-name>, <string-name><surname>Karimi</surname><given-names>G.</given-names></string-name></person-group><article-title>The role of microRNAs on doxorubicin drug resistance in breast cancer</article-title>. <source>J. Pharm. Pharmacol.</source><year>2021</year>; <volume>73</volume>:<fpage>997</fpage>–<lpage>1006</lpage>.<pub-id pub-id-type="pmid">33942851</pub-id></mixed-citation>
    </ref>
    <ref id="B91">
      <label>91.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhan</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>T.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>K.</given-names></string-name></person-group><article-title>Beta-sitosterol reverses multidrug resistance via BCRP suppression by inhibiting the p53–MDM2 interaction in colorectal cancer</article-title>. <source>J. Agric. Food Chem.</source><year>2020</year>; <volume>68</volume>:<fpage>3850</fpage>–<lpage>3858</lpage>.<pub-id pub-id-type="pmid">32167760</pub-id></mixed-citation>
    </ref>
    <ref id="B92">
      <label>92.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nixon</surname><given-names>M.</given-names></string-name>, <string-name><surname>Mackenzie</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>A.I.</given-names></string-name>, <string-name><surname>Homer</surname><given-names>N.Z.</given-names></string-name>, <string-name><surname>Livingstone</surname><given-names>D.E.</given-names></string-name>, <string-name><surname>Mouras</surname><given-names>R.</given-names></string-name>, <string-name><surname>Morgan</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Mole</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Stimson</surname><given-names>R.H.</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>R.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>ABCC1 confers tissue-specific sensitivity to cortisol versus corticosterone: a rationale for safer glucocorticoid replacement therapy</article-title>. <source>Sci. Transl. Med.</source><year>2016</year>; <volume>8</volume>:<fpage>352ra109</fpage>.</mixed-citation>
    </ref>
    <ref id="B93">
      <label>93.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>B.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Mou</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>MMEASE: online meta-analysis of metabolomic data by enhanced metabolite annotation, marker selection and enrichment analysis</article-title>. <source>J. Proteomics</source>. <year>2021</year>; <volume>232</volume>:<fpage>104023</fpage>.<pub-id pub-id-type="pmid">33130111</pub-id></mixed-citation>
    </ref>
    <ref id="B94">
      <label>94.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Evangelista</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Lemaitre</surname><given-names>R.N.</given-names></string-name>, <string-name><surname>Sotoodehnia</surname><given-names>N.</given-names></string-name>, <string-name><surname>Gharib</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Totah</surname><given-names>R.A.</given-names></string-name></person-group><article-title>CYP2J2 expression in adult ventricular myocytes protects against reactive oxygen species toxicity</article-title>. <source>Drug Metab. Dispos.</source><year>2018</year>; <volume>46</volume>:<fpage>380</fpage>–<lpage>386</lpage>.<pub-id pub-id-type="pmid">29343610</pub-id></mixed-citation>
    </ref>
    <ref id="B95">
      <label>95.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sobolev</surname><given-names>V.V.</given-names></string-name>, <string-name><surname>Soboleva</surname><given-names>A.G.</given-names></string-name>, <string-name><surname>Denisova</surname><given-names>E.V.</given-names></string-name>, <string-name><surname>Pechatnikova</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Dvoryankova</surname><given-names>E.</given-names></string-name>, <string-name><surname>Korsunskaya</surname><given-names>I.M.</given-names></string-name>, <string-name><surname>Mezentsev</surname><given-names>A.</given-names></string-name></person-group><article-title>Proteomic studies of psoriasis</article-title>. <source>Biomedicines</source>. <year>2022</year>; <volume>10</volume>:<fpage>619</fpage>.<pub-id pub-id-type="pmid">35327421</pub-id></mixed-citation>
    </ref>
    <ref id="B96">
      <label>96.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mazerska</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Mroz</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pawlowska</surname><given-names>M.</given-names></string-name>, <string-name><surname>Augustin</surname><given-names>E.</given-names></string-name></person-group><article-title>The role of glucuronidation in drug resistance</article-title>. <source>Pharmacol. Ther.</source><year>2016</year>; <volume>159</volume>:<fpage>35</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">26808161</pub-id></mixed-citation>
    </ref>
    <ref id="B97">
      <label>97.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>W.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>B.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Lian</surname><given-names>X.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>SYNBIP: synthetic binding proteins for research, diagnosis and therapy</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D560</fpage>–<lpage>D570</lpage>.<pub-id pub-id-type="pmid">34664670</pub-id></mixed-citation>
    </ref>
    <ref id="B98">
      <label>98.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>D.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Zou</surname><given-names>Q.</given-names></string-name></person-group><article-title>webTWAS: a resource for disease candidate susceptibility genes identified by transcriptome-wide association study</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1123</fpage>–<lpage>D1130</lpage>.<pub-id pub-id-type="pmid">34669946</pub-id></mixed-citation>
    </ref>
    <ref id="B99">
      <label>99.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xia</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>L.</given-names></string-name>, <string-name><surname>Fang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>PFmulDL: a novel strategy enabling multi-class and multi-label protein function annotation by integrating diverse deep learning methods</article-title>. <source>Comput. Biol. Med.</source><year>2022</year>; <volume>145</volume>:<fpage>105465</fpage>.<pub-id pub-id-type="pmid">35366467</pub-id></mixed-citation>
    </ref>
    <ref id="B100">
      <label>100.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hong</surname><given-names>J.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ying</surname><given-names>J.</given-names></string-name>, <string-name><surname>Xue</surname><given-names>W.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>T.</given-names></string-name>, <string-name><surname>Tao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name></person-group><article-title>Protein functional annotation of simultaneously improved stability, accuracy and false discovery rate achieved by a sequence-based deep learning</article-title>. <source>Brief. Bioinform.</source><year>2020</year>; <volume>21</volume>:<fpage>1437</fpage>–<lpage>1447</lpage>.<pub-id pub-id-type="pmid">31504150</pub-id></mixed-citation>
    </ref>
    <ref id="B101">
      <label>101.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barrett</surname><given-names>T.</given-names></string-name>, <string-name><surname>Wilhite</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Ledoux</surname><given-names>P.</given-names></string-name>, <string-name><surname>Evangelista</surname><given-names>C.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>I.F.</given-names></string-name>, <string-name><surname>Tomashevsky</surname><given-names>M.</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>K.A.</given-names></string-name>, <string-name><surname>Phillippy</surname><given-names>K.H.</given-names></string-name>, <string-name><surname>Sherman</surname><given-names>P.M.</given-names></string-name>, <string-name><surname>Holko</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>NCBI GEO: archive for functional genomics data sets—update</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>D991</fpage>–<lpage>D995</lpage>.<pub-id pub-id-type="pmid">23193258</pub-id></mixed-citation>
    </ref>
    <ref id="B102">
      <label>102.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gautier</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cope</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bolstad</surname><given-names>B.M.</given-names></string-name>, <string-name><surname>Irizarry</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Affy—analysis of affymetrix genechip data at the probe level</article-title>. <source>Bioinformatics</source>. <year>2004</year>; <volume>20</volume>:<fpage>307</fpage>–<lpage>315</lpage>.<pub-id pub-id-type="pmid">14960456</pub-id></mixed-citation>
    </ref>
    <ref id="B103">
      <label>103.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chin</surname><given-names>L.</given-names></string-name>, <string-name><surname>Hahn</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Getz</surname><given-names>G.</given-names></string-name>, <string-name><surname>Meyerson</surname><given-names>M.</given-names></string-name></person-group><article-title>Making sense of cancer genomic data</article-title>. <source>Genes Dev.</source><year>2011</year>; <volume>25</volume>:<fpage>534</fpage>–<lpage>555</lpage>.<pub-id pub-id-type="pmid">21406553</pub-id></mixed-citation>
    </ref>
    <ref id="B104">
      <label>104.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>GTEx Consortium</collab></person-group>, <article-title>Genetic effects on gene expression across human tissues</article-title>. <source>Nature</source>. <year>2017</year>; <volume>550</volume>:<fpage>204</fpage>–<lpage>213</lpage>.<pub-id pub-id-type="pmid">29022597</pub-id></mixed-citation>
    </ref>
    <ref id="B105">
      <label>105.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldman</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Craft</surname><given-names>B.</given-names></string-name>, <string-name><surname>Hastie</surname><given-names>M.</given-names></string-name>, <string-name><surname>Repecka</surname><given-names>K.</given-names></string-name>, <string-name><surname>McDade</surname><given-names>F.</given-names></string-name>, <string-name><surname>Kamath</surname><given-names>A.</given-names></string-name>, <string-name><surname>Banerjee</surname><given-names>A.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Rogers</surname><given-names>D.</given-names></string-name>, <string-name><surname>Brooks</surname><given-names>A.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Visualizing and interpreting cancer genomics data via the xena platform</article-title>. <source>Nat. Biotechnol.</source><year>2020</year>; <volume>38</volume>:<fpage>675</fpage>–<lpage>678</lpage>.<pub-id pub-id-type="pmid">32444850</pub-id></mixed-citation>
    </ref>
    <ref id="B106">
      <label>106.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ge</surname><given-names>X.</given-names></string-name>, <string-name><surname>Yamamoto</surname><given-names>S.</given-names></string-name>, <string-name><surname>Tsutsumi</surname><given-names>S.</given-names></string-name>, <string-name><surname>Midorikawa</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ihara</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Aburatani</surname><given-names>H.</given-names></string-name></person-group><article-title>Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues</article-title>. <source>Genomics</source>. <year>2005</year>; <volume>86</volume>:<fpage>127</fpage>–<lpage>141</lpage>.<pub-id pub-id-type="pmid">15950434</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
